Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Nxera Pharma's Partner Centessa Initiates Phase 2 Trial of ORX750
Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1/2.
Product Name : ORX750
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nxera Pharma Receives Approval of Insomnia Drug in Japan
Details : Quviviq (daridorexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nxera Pharma Gains Approval for QUVIVIQ in Japan to Treat Insomnia
Details : Quviviq (daridorexant) is a dual orexin receptor antagonist. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of adult patients with insomnia.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $1,200.0 million
Deal Type : Collaboration
Nxera Receives US$10 Million from AbbVie for Neurological Diseases Milestone
Details : The collaboration aims to leverage Nxera’s NxWave platform to discover and commercialize new medicines targeting novel G protein-coupled receptor targets associated with neurological disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $1,200.0 million
Deal Type : Collaboration
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Formosa Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals
Details : APP13007 (clobetasol propionate) is a nanoparticle steroid formulation for treating inflammation and pain post-cataract surgery, with milestone payments to Sosei Heptares based on pipeline progress.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
June 03, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Formosa Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : PrecisionLife
Deal Size : Undisclosed
Deal Type : Partnership
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
Details : The strategic R&D partnership for the auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : PrecisionLife
Deal Size : Undisclosed
Deal Type : Partnership
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.
Product Name : ORX750
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Licensing Agreement
Nxera Pharma Reports Progress On Partnered Schizophrenia Candidate NBI-1117568
Details : Under the license, Neurocrine gains development and commercialization rights to a portfolio of novel clinical and preclinical muscarinic M4 receptor agonists, NBI-1117568 for treating schizophrenia.
Product Name : NBI-1117568
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
April 16, 2024
Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : HANDOK
Deal Size : Undisclosed
Deal Type : Agreement
Nxera Pharma Announces Exclusive Supply Agreement with Handok for Pivlaz™
Details : Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Product Name : Pivlaz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 14, 2024
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : HANDOK
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Shionogi
Deal Size : Undisclosed
Deal Type : Partnership
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
Details : Under the partnership, Nxera will be responsible for providing Quviviq (daridorexant) for the Japanese market, and Shionogi will be exclusively responsible for distribution and sales in Japan.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 10, 2024
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Shionogi
Deal Size : Undisclosed
Deal Type : Partnership